Adverse effects of therapy for ANCA-associated vasculitis.

Research output: Contribution to journalArticle


Colleges, School and Institutes


The introduction of cyclophosphamide- and prednisolone-based treatment regimens has significantly improved outcome in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. However, these regimens are nonspecific immunosuppressants associated with significant toxicity, including increased risk of infection, leucopenia, diabetes and malignancy. In addition, disease damage, particularly renal failure, increases the risk of toxicity. Improvements in disease management should include the increased awareness of treatment-related toxicity and its prevention.


Original languageEnglish
Pages (from-to)391-401
Number of pages11
JournalBest Practice & Research: Clinical Rheumatology
Issue number3
Publication statusPublished - 1 Jun 2009


  • immunosuppression, toxicity, adverse events, ANCA-associated vasculitis, infection